Analysts credit the Oncobiota microbiome-driven liquid biopsy platform for identifying
the “infinite potential” of using microbiome markers to diagnose cancer.
March 29, 2023. SAN DIEGO, Calif.–Based on an independent team of expert’s
rigorous evaluation of a broad field of nominated companies, Frost & Sullivan has
selected Micronoma, the first biotech company offering early cancer detection with a
microbiome-driven liquid biopsy platform, to receive this year’s Best Practices
Technology Innovation Leadership Award in the North America liquid biopsy for lung
“Driving innovation and growth is a difficult task made even harder by the strategic
imperatives forcing change today, such as disruptive technologies, value chain
compression, and industry convergence,” Frost & Sullivan said. “In this context,
Micronoma’s recognition signifies an even greater accomplishment.”
Noting that lung cancer has one of the highest mortality rates, the panel concluded that
Micronoma’s Oncobiota™ platform delivers improved diagnostic capabilities that can
result in better patient outcomes and lower costs. OncobiotaLUNG was recently
granted FDA Breakthrough Designation Devices status.
Frost & Sullivan, a research-based think tank focused on supporting the public and
private sectors on their journey to visionary innovation, credited Micronoma for
distinguishing itself compared to competitors based on performance in numerous
technology and business best practice categories, including commitment to innovation,
creativity and growth potential in a rapidly expanding market.
“We’re extremely gratified to receive this award that recognizes the revolutionary
advances Micronoma is making in early cancer detection,” Sandrine Miller-Montgomery,
Micronoma CEO and co-founder said. “Our unwavering commitment to offering a
minimally invasive diagnostic option to clinicians and patients, starting with lung cancer,
should be ready for clinicians this year. Our technology has vast potential to reduce the
need for costly and sometimes dangerous tissue biopsies and, most importantly, help
patients lead longer lives.”
To learn more about Micronoma, please go to Micronoma.com.
Micronoma is the first cancer-detection company utilizing signals from circulating
microbial nucleic acids in blood to diagnose cancer at an early stage with microbiome-
driven liquid biopsy technology. Micronoma was founded in 2019 by leaders in
microbiome research with the goal of advancing early cancer diagnostics and
personalized treatment through sensitive microbiome techniques, ensuring that patients’
needs are met by their clinicians at the earliest stage for a better chance to live longer,
healthier lives. The company is headquartered in San Diego, California.